Therapeutic Response

BRCA2 pathogenic variants status confers therapeutic sensitivity to Abiraterone acetate in combination with Niraparib and Prednisolone in patients with Prostate Adenocarcinoma.

Statements

Source and description

Akeega (abiraterone acetate and niraparib) [product monograph]. HC. Health Canada approved niraparib and abiraterone acetate in combination with prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (mCRPC), who are asymptomatic or mildly symptomatic, and in whom chemotherapy is not clinically indicated.